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Abstract
15-Deoxy-Δ12,14-prostaglandin-J2 (15d-PGJ2), a peroxisome proliferator–activated receptor γ (PPARγ) agonist, in-
duces cell death in tumor cells in vitro; however, no study showed its in vivo effect on tumors. Here, we report
that 15d-PGJ2 shows antitumor effects in vivo in mice. However, its effects correlate with tumor uptake of albu-
min, to which it reversibly binds. 15d-PGJ2 induces cell death in B16F10 melanoma and C26 colon carcinoma cells
in vitro. These effects were not elicited through PPARγ-dependent pathways because an irreversible PPARγ antag-
onist GW9662 did not inhibit these effects. Caspase- and nuclear factor κB– (NF-κB) dependent pathways were
found to be involved as determined with caspase-3/7 fluorescent assay and NF-κB containing plasmid transfection
assay, respectively. Noticeably, 15d-PGJ2 had significantly stronger effects in C26 cells compared with B16 cells in
all assays. However, in vivo, there was no effect on C26 tumors, yet it significantly inhibited the B16 tumor growth
in mice by 75%. We found that 15d-PGJ2 rapidly bound to albumin and in vivo albumin greatly distributed to B16
tumors compared with C26 tumors, shown with γ-camera imaging and immunohistochemical staining. Albumin
accumulation can be attributed to the large blood vessel diameter in B16 tumors and an enhanced permeability
and retention effect. These findings suggest that 15d-PGJ2 can be an effective therapeutic agent for cancer, al-
though its effects seem to be limited to the tumors allowing albumin penetration.
Neoplasia (2009) 11, 1348–1358
Introduction
Prostaglandins are the hormone-like lipids produced locally by a va-
riety of cells in response of external stimuli. They play a crucial role in
the regulation of smooth muscle tone, homeostasis, inflammation, cel-
lular growth, and differentiation [1]. Among all prostaglandins, 15-
deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), a metabolite of PGD2,
has a unique property to activate the nuclear receptor peroxisome
proliferator–activated receptor γ (PPARγ) [2]. 15d-PGJ2 is a highly
interesting prostaglandin because it possesses multiple pharmaco-
logical activities, such as anti-inflammatory, antifibrotic, and apop-
totic activities [3–7]. However, it has been shown that intracellular
levels of 15d-PGJ2 (pM range) are far below the concentrations (2.5-
100 μM) required to exert its pharmacological effects [8]. Consider-
ing the potent biologic effects of 15d-PGJ2 in vitro and its in vivo
effect on key processes of inflammation, regeneration and tissue
growth, exogenous administration of 15d-PGJ2 may be quite relevant
but insight in factors that control its local effectiveness is warranted.
This is true for many prostaglandins, but in particular, the potential
applications of 15d-PGJ2 are quite unclear. Although 15d-PGJ2 has
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been found to elicit its pharmacological effects through PPARγ-
dependent pathway, several studies have also shown that it can act
through many PPARγ-independent pathways such as nuclear factor
κB (NF-κB)–, Keap-Nrf2–, and p53-dependent pathways [7,9,10].
In literature, 15d-PGJ2 has been shown to induce apoptosis-
mediated cell death in a variety of tumor cells in vitro [11–15]. How-
ever, there are nearly no data showing beneficial effects of 15d-PGJ2
in tumor models in vivo. Fulzele et al. [16] demonstrated that treat-
ment with 15d-PGJ2 enhanced the antitumor effects of docetaxel in
animal tumor models, but 15d-PGJ2 did not show any inhibitory ef-
fects by itself. The reason for the ineffectiveness of 15d-PGJ2 in vivo
might be due to the loss of its biologic activity in the presence of
serum as demonstrated in cell culture systems [17,18]. Conversely,
many studies have shown the in vivo therapeutic effects of 15d-
PGJ2 in inflammatory diseases such as acute pancreatitis [19] and
ischemia-reperfusion injuries in heart, brain, kidneys, and gut [20–
24]. Therefore, it can be assumed that 15d-PGJ2 remains pharmaco-
logically active in vivo after systemic administration. However, there
might be some factors that regulate the efficacy of 15d-PGJ2 in vivo.
In the present study, we investigated the effects of 15d-PGJ2
in two different tumor cell types, that is, B16F10 melanoma and
C26 colon carcinoma in vitro and furthermore investigated its mech-
anism of action in these cells. In addition, we compared its in vivo
efficacy in the subcutaneously induced tumors from these cells in
mice. We found that the in vivo effectiveness of 15d-PGJ2 did not
correlate with our in vitro results. To that end, we explored the fol-
lowing in more detail: 1) interaction of 15d-PGJ2 with the serum
protein albumin, 2) distribution of albumin in both tumor types,
and 3) effect of tumor vascularization on the albumin uptake in these
tumors to determine the reason for the difference between in vitro
and in vivo efficacy of 15d-PGJ2.
Materials and Methods
Materials
Mouse colon carcinoma cells (C26) were kindly provided by Prof.
Molema (Medical Biology, University Medical Centre Groningen,
the Netherlands) and mouse melanoma cells (B16F10) were bought
from American Type Culture Collection (ATCC, Rockville, MD).
Monoclonal rat-antimouse platelet endothelial cell adhesion molecule-1
(CD31) was purchased from BD PharMingen (San Diego, CA), and
was purchased from rabbit–anti–human serum albumin (HSA)
from ICN Biomedics (Eschwege, Germany). Human serum albumin
(HSA; GMP-grade Cealb) was purchased from Sanquin (Amsterdam,
Netherlands), and mouse serum albumin (fraction V) was bought
from Sigma (St Louis, MO). Mouse tumor necrotic factor α (TNF-α)
was bought from Peprotech (Rocky Hill, NJ). GW9662 (2 chloro 5-
nitrobenzanilide) was purchased from Sigma.
Immunohistochemistry and Immunocytochemistry
From isopentane-fixed tissues, 4-μm-thick frozen sections were
made with a cryostat (Leica, Nussloch, Germany) to perform immuno-
histochemical staining. Sections were fixed in acetone for 20 minutes,
and cells were fixed in acetone-methanol (1:1) at −20°C for 1 hour. Sec-
tions or cells were dried under blowing air, rehydrated in phosphate-
buffered saline (PBS), and then incubated with primary antibody of
interest for 1 hour. After three washings with PBS, endogenous peroxi-
dase activity was blocked with 0.05% hydrogen peroxide by incubating
for 20 minutes only in case of tissue sections. Then, sections/cells were
incubated with horseradish peroxidase–labeled secondary antibody for
30 minutes after three washings with PBS. Then, samples were washed
three times with PBS and incubated with 3-amino-9-ethyl carbazole so-
lution for 20 minutes. Subsequently, samples were washed in distilled
water and incubated with hematoxylin for nuclear staining. After this,
tissue sections or cells were mounted with glycerol/kieselguhr solution
after washing in tap water. Staining was visualized under a light micro-
scope (Olympus BX41, Tokyo, Japan).
We analyzed CD31 staining (endothelial cell marker) for the de-
termination of the blood vessel lumen area and blood vessel density
in tumor sections of B16 and C26 tumors using NIH Image soft-
ware (Image J; National Institutes of Health, Bethesda, MD). To mea-
sure blood vessel lumen area, we randomly selected approximately
40 blood vessels of B16 tumor and 100 blood vessels of C26 tumor
per animal in three mice and drew a line around the CD31 staining
digitally and measured the area of the drawn circle with the software.
For measuring the blood vessel density, we counted the number of
blood vessels in three to four different tumor fields per animal at the
magnification of ×100 in n = 3 mice for each tumor.
Cell Experiments
B16 and C26 cells were maintained on Dulbecco’s modified Ea-
gle’s medium (BioWhittaker, Verviers, Belgium) supplemented with
10% fetal calf serum (FCS) and antibiotics (50 U/ml penicillin plus
50 ng/ml streptomycin for B16 and 10 μg/ml gentamicin for C26 cells)
at 37°C in a humidified incubator containing 5% carbon dioxide.
Cell growth determination. Cells were seeded into the 96-well
plate as 1 × 104 cells/well in 200 μl medium with 10% FCS. After
24 hours, cells were washed with serum-free medium and then in-
cubated with different concentrations of 15d-PGJ2 in serum-free me-
dium for 48 hours. In case of treatment with GW9662, cells were
preincubated with GW9662 (10 μM) for 3 hours and then incubated
with a mixture of 15d-PGJ2 and GW9662 for 48 hours. For other
treatments such as FCS and HSA, cells were incubated with 15d-
PGJ2 simultaneously. Cell growth was determined using alamarBlue
dye (Serotec, Oxford, UK), which reflects the number of cells on
the basis of mitochondrial activity. After 48 hours of incubation, cells
were added with the medium containing the alamarBlue Dye (di-
luted 1:10) and incubated for 4 hours, and thereafter, the metabolized
dye (fluorescent) was detected with a fluorimeter at an excitation of
560 nm and an emission of 590 nm.
Caspase 3/7 enzyme assays. Caspase-3 and -7 enzymes activity was
determined using Caspase 3/7 Glo Assay Kit (Promega, Madison, WI).
A total of 1 × 104 cells were seeded in 96-well plate in 200 μl of cultur-
ing medium. After 24 hours, cells were washed with serum-free me-
dium and incubated with different concentrations of 15d-PGJ2 in a
100-μl medium for 5.5 hours. Subsequently, 100 μl of the caspase 3/7
reconstituted reagent was added to the cells and incubated for 30 min-
utes in the incubator. The luminescence was determined by a lumino-
meter (Lumicount; Packard, Meriden, CT).
Transfection and luciferase assay for NF-κB activity. The activity
of NF-κB was determined with a Luciferase assay using a Luciferase
plasmid DNA, pNF-κB-Luc (Clontech, Mountain View, CA), which
contains a specific binding sequence for NF-κB. An empty Luciferase
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plasmid, pTAL-Luc was used as a control. In brief, 1 × 104 cells per
well were seeded in 96-well plates, and the transfection of the plas-
mid was carried out using FuGENE 6 Transfection Reagent (Roche,
Mannheim, Germany) after 24 hours. Cells were treated with a com-
plex of 0.17 μg of DNA/0.5 μl of FuGENE 6 in 100 μl of normal
medium with 10% FCS for 24 hours. Subsequently, cells were
washed once with serum-free medium and incubated with 15d-
PGJ2 with or without TNF-α for 4 hours. Thereafter, cells were
washed with PBS and lysed with 20 μl of lysis buffer and added with
100 μl of Luciferase substrate (Promega). Luciferase activity was
measured by a luminometer (Lumicount; Packard). The lumines-
cence unit values of pNF-κB-Luc were neutralized by subtracting
the pTAL-Luc values.
Binding Studies of 15d-PGJ2 to Albumin
To determine the binding of 15d-PGJ2 with HSA and mouse al-
bumin, 15d-PGJ2 (10 μM dissolved in PBS) was incubated with
HSA (30 and 80 μM in PBS) and mouse albumin (30 μM) for
15 minutes and 3 hours at 37°C. At specific time points, samples were
taken out and put into the centrifuge dialysis tubes (Microcon, cutoff
10 kDa; Millipore, Bedford, MA) and centrifuged for 20 minutes at
×14,000 rpm to separate unbound 15d-PGJ2. The filtrate from the
centrifuge tube was collected, and 25 μl of it was injected into an
HPLC system (Waters, Milford, MA) to quantify 15d-PGJ2. Control
tubes with 10 μM 15d-PGJ2 alone were included and processed in the
similar way to examine the percentage recovery from the centrifuge
dialysis tubes. HPLC determination of 15d-PGJ2 was performed with
Chromolith SpeedROD column (Merck, Darmstadt, Germany) with
eluents (acetonitrile/H2O/trifluoroacetic acid, 50:50:0.1) at a flow rate
of 1 ml/min. 15d-PGJ2 was detected using a UV detector at 306 nm
and quantified using EmPower software (Waters).
To investigate whether 15d-PGJ2 was covalently bound to albumin,
we used fast protein liquid chromatography system (FPLC, AKTA;
Amersham Biosciences, Uppsala, Sweden). 15d-PGJ2 (10 μM) was
incubated with HSA (80 μM) overnight at 37°C. Thereafter, the
mixture was injected into a FPLC system equipped with gel filtra-
tion column (Superdex 200; Amersham Biosciences) and UV detec-
tor (214 nm).
Subcutaneous Tumor Model in Mice
Normal male C57BL/6 and Balb/c mice weighing 20 to 25 g were
obtained from Harlan (Zeist, the Netherlands). They were kept at a
12:12-hour light/dark cycle and received ad libitum normal diet. All
experimental protocols for animal studies were approved by the Ani-
mal Ethics Committee of the University of Groningen. To induce
subcutaneous tumors, B16F10 cells and C26 cells were cultured in
125-mm3 flasks a day before injection in animals to keep them in the
growth phase. Cells were detached by trypsanization, and trypsin was
Figure 1. Effect of 15d-PGJ2 on the growth of B16 and C26 cells. (A) 15d-PGJ2 induced cell death in both B16 and C26 tumor cells.
However, the effects were significantly higher in C26 cells compared with B16 cells. (B) Incubation of control cells with the PPARγ
antagonist GW9662 (10 μM) and 5% FCS affected the cell growth of both cell types. (C) Pretreatment with GW9662 did not inhibit
the effect of 15d-PGJ2 in both cell types indicating the PPARγ-independent effects of 15d-PGJ2. (D) Incubation of 15d-PGJ2 in the pres-
ence of FCS reduced its effects in both cell types. Data are presented as relative fluorescence unit that was calculated by fixing the
intensity of fluorescent product of alamarBlue dye for untreated cells at 100. Data represent the average of at least three separate
experiments. Statistical differences between B16 and C26 cells are shown as *P < .05, **P < .01.
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removed by centrifugation. The cell pellet was resuspended in PBS. A
total of 1 × 106 cells (B16 and C26 cells) suspended in 100 μl of PBS
were injected subcutaneously in the flank of C57BL/6 and Balb/c
mice, respectively. Tumor growth was followed by measuring tumor
size using a digital Vernier caliper. Tumor volume was established using
the formula: a × b2 / 2, where a denotes tumor length and b denotes
the tumor width.
Effect of 15d-PGJ2 on tumor growth. B16 and C26 tumors were
induced in mice as described previously. The treatment was started on
day 5 when the tumor volume was reached the range of 50 to 100 mm3
because this tumor size has been shown as an optimum tumor size
for the start of the treatment [25,26]. Animals were injected intrave-
nously with four doses of either vehicle (PBS) or 15d-PGJ2 (2 mg/kg
per day) on alternative days under anesthesia (O2/isoflurane). Tumor
size was measured under anesthesia. Animals with B16 tumors were
killed on day 13 as the tumor volume in some animals reached to
2000 mm3 (maximally allowed by the ethical guidelines), whereas
the animals with C26 tumors were killed on day 15 because no effect
of the treatment was observed. Animals were killed under gas anesthe-
sia (O2/isoflurane), and tumors were isolated and fixed in cold iso-
pentane for cryosections.
γ-Camera imaging of 123I-HSA and tumor distribution of
HSA. HSA was radiolabeled with radioiodine (123I) using NBS
method on the same day of the experiment as explained elsewhere
[27]. The tracer doses (3-4 MBq) of 123I-labeled HSA were injected
intravenously into tumor-bearing mice through penile vein under an-
esthesia (O2/isoflurane). Two hours after injection, animals were
scanned with a γ-camera for 10 minutes under ketamine/diazepam
anesthesia. Subsequently, the same animals were rescanned at t =
24 hours. The experiments were performed in three animals per time
point for each tumor type.
To localize HSA in both B16 and C26 tumors, HSA (1 mg per
mouse) was injected intravenously into the tumor-bearing mice. After
2 hours, animals were killed, and tumors were isolated and fixed in
cold isopentane. Tumor tissues were processed for immunohistochem-
ical analyses using anti-HSA antibody as described previously.
Statistical Analyses
Data are presented as mean ± SEM unless otherwise mentioned.
The statistical analyses were performed using Student’s t-test with P <
.05 as the minimal level of significance. AlamarBlue data were fitted
for sigmoidal dose-response curve to calculate the half maximal in-
hibitory concentration (IC50) using GraphPad Prism 4 software (La
Jolla, CA).
Results
15d-PGJ2 Induces Cell Death in B16 and C26 Cells
PPARγ-Independently
Treatment with 15d-PGJ2 caused cell death in both B16 and C26
cells in a dose-dependent manner (Figure 1A). 15d-PGJ2 showed a
significantly higher efficacy in C26 cells (IC50 = 1.52 μM) compared
with the B16 cells (IC50 = 4.52 μM). Although 15d-PGJ2 is known
to induce its effects through the PPARγ pathway, we found that cell
death in these cells was PPARγ-independent because pretreatment
with the irreversible PPARγ antagonist GW9662 did not block the
effects of 15d-PGJ2 (Figure 1C). Also, in the presence of GW9662,
C26 cells were found to be more sensitive than B16 cells for the treat-
ment with 15d-PGJ2. Furthermore, we found that the presence of
serum substantially reduced the growth-inhibiting effect of 15d-PGJ2
in both cell types (Figure 1D). The inhibition of this effect might
be due to the binding of 15d-PGJ2 to the serum proteins [17]. These
data suggest that in vivo, 15d-PGJ2 might become ineffective owing
to the presence of a large amount of serum proteins in circulation.
15d-PGJ2 Induces Apoptosis by Inhibiting NF-κB Pathway
To confirm that 15d-PGJ2 caused cell death in B16 and C26 cells
through apoptotic pathways, we determined the activities of caspase-3
Figure 2. Effect of 15d-PGJ2 on the caspase 3/7 activity and NF-κB
activity in B16 and C26 cells. (A) Caspase 3/7 enzyme activity was
determined in cells using a luminescence assay after the incubation
with different amount of 15d-PGJ2 for 5.5 hours as described in the
Materials and Methods section. Data show that the caspase 3/7
activity was induced in both cell types by 15d-PGJ2 concentration-
dependently. However, C26 cells had significantly higher activity
than B16 cells. (B) For NF-κB activity, both B16 and C26 cells were
transiently transfected with a plasmid containing NF-κB promoter
with luciferase reporter element (pNF-κB-Luc) for 24 hours. In paral-
lel, an empty plasmid with only luciferase activity (pTAL-Luc) was
used as a control. After 24 hours, 15d-PGJ2 was incubated with
and without TNF-α for 4 hours, and then luciferase activity was mea-
sured using luminescence assay to determine the NF-κB activity.
The values (relative light units) of the pNF-κB-Luc were neutralized
by subtracting the values of the control plasmid pTAL-Luc. The
NF-κB pathway activator, TNF-α, induced the NF-κB activity in both
cell types and treatment with 15d-PGJ2 significantly inhibited it. In
control cells, inhibitory effects of 15d-PGJ2 were more pronounced
in C26 cells. Data represent for the average of at least three sepa-
rate experiments. Statistical differences versus the respective con-
trols are shown as #P < .05 and ##P < .01 and other differences
are *P < .05, **P < .01.
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and -7, the effector enzymes in apoptosis pathway. We found that
15d-PGJ2 caused a concentration-dependent increase in caspase-3
and -7 enzymes activity in both cell types after 6 hours of incubation.
Again, the activity was significantly higher in C26 cells than in B16
cells (Figure 2A). These data suggest that C26 cells respond to 15d-
PGJ2 more promptly than B16 cells through activation of the apop-
tosis cascade.
Because the cell death induced by 15d-PGJ2was PPARγ-independent,
we investigated the involvement of NF-κB pathway, an important
regulator of cell apoptosis and proliferation, in B16 and C26 cells
using the NF-κB luciferase reporter assay. To induce the NF-κB ac-
tivity in these cells, we used TNF-α, which is a direct activator of
NF-κB pathway. We found that treatment with TNF-α (50 and
100 ng/ml) significantly enhanced the NF-κB reporter activity (B16
cells, 3.7- and 5.2-fold, respectively, and C26 cells, 1.6- and 7.0-fold,
respectively), which was in turn completely inhibited by 15d-PGJ2
(Figure 2B). In addition, 15d-PGJ2 also reduced the NF-κB activity
in TNF-α–untreated cells. Similar to the studies mentioned previ-
ously, the effect was greater in C26 than in B16 cells. These re-
sults demonstrate that 15d-PGJ2 induces apoptosis in both B16 and
Figure 3. In vivo effects of 15d-PGJ2 on the tumor growth B16 and C26 tumors. B16 and C26 tumor-bearing mice were treated either
with PBS or 15d-PGJ2 (2 mg/kg per day) intravenously. Treatment with 15d-PGJ2 significantly (*P < .05, **P < .01 vs vehicle group)
retarded the progression of B16 tumors (A), whereas no effect found on the growth of C26 tumors (B). Data represent the average of six
animals per group for all groups. (C) Representative microscopic pictures of the endothelial cell marker CD31 staining showing the effect
of 15d-PGJ2 on the vasculature of B16 and C26 tumors. Treatment with 15d-PGJ2 disrupted the blood vessels in B16 tumors, whereas
there was no effect on the vasculature of C26 tumors.
Table 1. Plasma Levels of ALT, AST, and Creatinine in Tumor-Bearing Mice to Determine the Effect of the 15d-PGJ2 Treatment on Liver and Renal Toxicity.
Tumor Models Treatment Groups ALT (U/L) AST (U/L) AST/ALT Ratio Creatinine (μM)
B16 tumor-bearing mice PBS (n = 5) 44.4 ± 7.2 602 ± 60.2 14.5 ± 2.0 7.80 ± 0.97
15d-PGJ2 35.2 ± 2.0 135 ± 20.1* 3.92 ± 0.6* 7.83 ± 1.0
C26 tumor-bearing mice PBS 18.8 ± 1.4 67.8 ± 6.5 3.73 ± 0.5 8.0 ± 1.2
15d-PGJ2 14.5 ± 1.7
† 56.2 ± 6.4 4.14 ± 0.8 9.67 ± 1.4
ALT indicates alanine aminotransferase; AST, aspartate aminotransferase.
n = 6 animals per group unless mentioned.
*P < .01, PBS versus 15d-PGJ2.
†P < .05, PBS versus 15d-PGJ2.
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C26 cells through common pathways involving caspase- and NF-κB–
dependent pathways.
15d-PGJ2 Reduces the Tumor Progression In Vivo
Because 15d-PGJ2 showed high cytotoxicity in vitro in both B16
and C26 cells, we further evaluated its efficacy in vivo in subcutaneous
tumor-bearing mice from these cells. In B16 tumors, we found that
treatment with 15d-PGJ2 significantly inhibited the progression of
tumors as shown in Figure 3 (A and B). These effects were visible
from the first dose of 15d-PGJ2, indicating a high efficacy of the treat-
ment. 15d-PGJ2–treated tumors had 80% lower tumor weight com-
pared with the vehicle-treated tumors (0.30 ± 0.13 vs 1.67 ± 0.37 g,
respectively, P < .01), and large necrotic area and disrupted vascula-
ture could be seen after CD31 immunostaining (Figure 3C). Surpris-
ingly, similar doses of 15d-PGJ2 had no effect on the tumor growth of
C26 tumors, although in vitro the C26 cells were more prone to the
15d-PGJ2 treatment compared with the B16 cells. Treatment with
15d-PGJ2 significantly reduced the raised alanine aminotransferase/
aspartate aminotransferase levels in B16 tumor-bearing mice (Table 1).
These data show that 15d-PGJ2 did not cause any liver and renal
toxicity in both tumor models (Table 1).
We set out to find the reason for this discrepancy in effectiveness
of 15d-PGJ2 in vitro and in vivo in both tumor models.
Binding of 15d-PGJ2 to Albumin Determines Its
Pharmacological Activity
We already showed that 15d-PGJ2 lost its effects in the presence of
serum in vitro (Figure 1D), and this could be the most likely cause of
its ineffectiveness in vivo. However, 15d-PGJ2 showed its anti–tumor
effects in B16 tumors but not in C26 tumors, which indicates that
there are more factors responsible for this discrepancy in effective-
ness. Because albumin is the major protein in serum and has been
shown to block the effects of 15d-PGJ2 in vitro [17], we examined
the binding of HSA to 15d-PGJ2. We found that 85% of 15d-PGJ2
was bound to HSA after a short incubation with three-fold molar
excess of HSA at 37°C, as determined by HPLC analysis after sepa-
rating the unbound 15d-PGJ2 using an ultrafiltration method (Fig-
ure 4A). A higher molar ratio of HSA (eight-fold) enhanced the
binding up to 90%. Because the in vivo effect studies were performed
in mice, we investigated binding of 15d-PGJ2 to mouse serum albu-
min. We found that 15d-PGJ2 was completely bound to the mouse
albumin (three-fold molar excess) within 15 minutes of incubation.
In our in vivo study, the molar ratio of 15d-PGJ2 to albumin is esti-
mated to be 1:7.5, which means that no 15d-PGJ2 was left unbound.
This binding of 15d-PGJ2 to albumin appeared to be noncovalent
and reversible because 15d-PGJ2 could be completely separated again
from HSA after an overnight incubation at 37°C in 1:8 (15d-PGJ2/
HSA) ratio, when the mixture was passed through a gel filtration col-
umn in an FPLC system (Figure 4B). Similar results were obtained
when the mouse albumin–15d-PGJ2 complex was put on gel filtra-
tion column (data not shown), indicating the reversibility of the 15d-
PGJ2 binding to albumin.
Subsequently, we examined whether HSA interferes in the activity
of 15d-PGJ2 in vitro in both cell types. We found that HSA reduced
the 15d-PGJ2 caused cell death in both B16 and C26 cells, although
the blockade was more pronounced in B16 cells (Figure 5). A 2.5-fold
molar excess of HSA was sufficient to block the effect of 15d-PGJ2
(10 μM) by 90% in B16 cells, but in C26 cells, the effects were
not blocked for more than 40% even with five-fold excess of HSA
(Figure 5, C and D). Because, in both cases, HSA binds to 15d-
PGJ2, we tested whether C26 cells might be able to internalize
HSA–15d-PGJ2 complex and release active 15d-PGJ2 intracellularly.
We therefore incubated B16 and C26 cells with HSA (30 μM) and
HSA (30 μM) plus 15d-PGJ2 (10 μM) for 24 hours and performed
anti-HSA staining after removing unbound protein by washing sev-
eral times. We found that C26 cells displayed significant staining for
HSA, whereas B16 cells showed no staining at all. These results in-
dicate that the 15d-PGJ2–HSA complex formed in the medium can
enter C26 cells. This may cause release of active 15d-PGJ2 leading to
the observed effects in this cell type. B16 cells do not take up this
complex in vitro.
Figure 4. In vitrobindingof 15d-PGJ2 to albumin. (A) 15d-PGJ2 (10μM)
rapidly bound to HSA (30 and 80 μM) within 15 minutes, and there
was a slight increase in the binding after 3 hours. 15d-PGJ2 and
HSA were incubated at 37°C and 100-μl samples were withdrawn
after 15minutes and 3 hours. Then the sampleswere passed through
the ultrafiltration units, and the filtrateswere determined for 15d-PGJ2
using the HPLC method. Data represent the percentage of the con-
centration of 15d-PGJ2 in the incubation solution, and the experi-
ments were done in triplicate. (B) Representative chromatogram of
the size-exclusion chromatography performed on 15d-PGJ2, HSA,
and themixture of 15d-PGJ2 and HSA (1:8) after their incubation over-
night at 37°C.
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Differences in the Tumor Vasculature Permits/Rejects
Albumin Tumor Uptake and Thereby May Influence the
Effect of 15d-PGJ2
From the mentioned results, we conclude that 15d-PGJ2 can bind
to albumin in a reversible manner immediately after intravenous in-
jection, and this profoundly attenuates the biologic effects of 15d-
PGJ2. In vitro, B16 tumor cells are less sensitive to 15d-PGJ2 and
are more affected by this inhibitory effect of albumin compared with
C26 tumors, yet in vivo the antitumor effect of 15d-PGJ2 is much
stronger in B16 tumors. Therefore, we assumed that tumor accessi-
bility of albumin might explain the differences in the effects of 15d-
PGJ2 in vivo. Because tumor penetration of albumin may depend on
the tumor vasculature, we determined the blood vessel lumen size
and blood vessel density in both B16 and C26 tumors of different
Figure 5. Effect of HSA on the effects of 15d-PGJ2 in both B16 and C26 cells. (A) Incubation of HSA in both cell types enhanced their
growth compared with the control cells in serum-free medium. #P < .05 and ##P < .01 show the differences versus the respective
controls. (B) Addition of HSA (30 μM) reduced the activity of 15d-PGJ2 in both cell types after 48 hours; however, these inhibitory effects
were significantly higher in B16 cells compared with C26 cells. Data represent the average of three experiments, and *P< .05 and **P<
.01 show the differences between B16 and C26 cells. (C) 15d-PGJ2 (10 μM) killed both tumor cell types almost completely, and the
addition of HSA blocked its activity with the increasing amounts. (D) However, in C26 cells, the growth did not reach to the maximal
level with the highest concentration of HSA. (E) Representative microscopic pictures of anti-HSA immunostaining in B16 and C26 cells.
A total of 4 × 104 cells/well were grown in 24-well plates and incubated with HSA (30 μM) and HSA (30 μM) plus 15d-PGJ2 (10 μM) for
24 hours and then washed three times with PBS, and anti-HSA immunostaining was performed. Red color showed the positive staining
for HSA in C26 cells, whereas there was no staining in B16 cells.
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sizes using CD31 immunostaining (an endothelial cell marker). We
found that blood vessel lumen size was increased with the size of
tumors in both tumor types (Figure 6, A–F ). Interestingly, in B16
tumors, the blood vessel lumen area was eight times larger than
C26 tumors, but the number of blood vessel per field was 7.5-fold
higher in C26 tumors than in B16 tumors as quantified in tumors of
similar size (Figure 6, G and H ). This shows that both tumor types
have a different vasculature. To determine whether tumor vasculature
induces a difference in the HSA uptake, we examined the uptake of
123I-HSA in B16 and C26 tumors using γ-camera imaging techniques.
Interestingly, B16 tumors had a high distribution and uptake of
HSA because tumors were clearly visible in the flank of the mice 2
and 24 hours after 123I-HSA injection (Figure 7A). In contrast, C26
tumors were not visible at any time point, suggesting the poor dis-
tribution of 123I-HSA to these tumors (Figure 7A). To confirm the
results, we examined the distribution of HSA in the tumor-bearing
Figure 6. Representative microscopic pictures of anti-CD31 immunostaining (endothelial cell marker) in B16 and C26 tumors. Pictures
show the difference in the tumor vasculature of B16 tumors (A, B, C) and C26 tumors (D, E, F) at their different sizes (A, D = 300-400 mm3;
B, E = 1300-1400 mm3; C, F =∼2000 mm3). The blood vessel lumen was found to be increased with the increase in the tumor size in both
tumor types. (G) Quantitative data for the blood vessel density (number of blood vessels per field) showed that C26 tumors have signif-
icantly higher number of blood vessels than B16 tumors. In contrast, B16 tumors had significantly larger lumen area of the blood vessels
than C26 tumors (H). These analyses were performed in B16 tumors (1616 ± 142 mm3) and in C26 tumors (1593 ± 233 mm3) from n =
3 mice for each tumor type. **P < .01.
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mice 2 hours after injection using immunostaining with anti-HSA
immunoglobulin G (Figure 7B). We found a strong staining of HSA
in B16 tumors around the blood vessels, whereas only a very faint
staining was present in C26 tumors. These results demonstrate that
B16 tumors have high HSA uptake compared with the C26 tu-
mors, and combined with the rapid and reversible binding of
15d-PGJ2 to albumin found in vitro, this explains the effects of
15d-PGJ2 in B16 tumors. Exogenous 15d-PGJ2 can be an effective
drug in tumor models, but its effectiveness in vivo is governed by
an enhanced permeability and retention effect and local release
from albumin.
Discussion
15d-PGJ2 is an endogenous cellular growth modulator and has been
shown to induce cytotoxic effects in vitro in different cancer cell types
[28]. However, there is a clear lack of data showing its efficacy in vivo
in animal tumor models. The present study demonstrates that 15d-
PGJ2 is able to inhibit the tumor progression effectively in a sub-
cutaneous tumor model in mice. However, these effects were found
to be dependent on its albumin-binding properties and on the char-
acteristics of tumor vasculature, rather than on the sensitivity of tumor
cells. 15d-PGJ2 induced cell death in vitro in two different tumor cell
types, namely, B16 melanoma and C26 colon carcinoma cells, through
NF-κB– and caspase-dependent pathways. C26 cells seemed to be the
most sensitive, but in vivo only B16 tumor growth was inhibited. We
showed that 15d-PGJ2 had a high binding affinity to albumin, and
therefore, albumin most likely acts as a carrier for 15d-PGJ2 in the
circulation. Furthermore, we demonstrated that B16 tumors had larger
blood vessel lumina compared with the C26 tumors and had a higher
distribution of radiolabeled albumin. These data suggest that in vivo
15d-PGJ2 may be highly effective in tumors with a vasculature that
allows an efficient and high albumin uptake.
In the last decade, the cell death–inducing effect of 15d-PGJ2 has
been studied extensively in cultured cells of various cellular carcinomas
such as breast, pancreatic, colon and gastric carcinomas, and B-cell
lymphoma [11–15,29–31]. In these reports, the effects of 15d-PGJ2
were shown to be mediated through PPARγ-dependent as well as
PPARγ-independent pathways. In addition, the PPARγ-dependency
Figure 7. Tumor distribution of HSA in tumor-bearing mice. (A) Representative γ-camera images showing the whole-body scans of the
tumor-bearing mice with B16 and C26 tumors at t = 2 hours and t = 24 hours after intravenous injection of the tracer doses of 123I-HSA.
Data demonstrate that 123I-HSA was rapidly distributed to the B16 tumors within 2 hours but not to the C26 tumors. Each picture is
representative of n = 2 to 3 mice. “T” denotes to the location of tumor in the flank of mice. Right multicolor bar indicates increase of the
radioactivity. (B) Representative microscopic pictures of the anti-HSA immunostaining in B16 and C26 tumors. Tumor-bearing mice were
intravenously injected with HSA (1 mg per mouse), and tumors were isolated after 2 hours and stained with anti-HSA immunoglobulin G
to localize HSA in tumors.
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was irrespective of the type of cellular carcinoma because 15d-PGJ2
inhibited the growth of different colon carcinoma cells through
PPARγ-dependent or -independent pathways [15,32–34]. In the pres-
ent study, we used two different carcinoma cell types to examine the
effect of 15d-PGJ2. However, there is no study showing the effect of
15d-PGJ2 in these tumor cells or on any other tumor model. Although
15d-PGJ2 is a PPARγ agonist, it exerted its cytotoxicity through
PPARγ-independent pathways as shown by the lack of any effect of
the irreversible PPARγ antagonist GW9662. Importantly, cell death in
both cell types was found to be induced through the common PPARγ-
independent mechanisms, namely, caspase- and NF-κB–dependent
pathways, as demonstrated by the induction of proapoptotic enzymes
caspase-3 and -7 and by the inhibition of the TNF-α–induced NF-κB
activity in NF-κB–containing plasmid-transfected cells. 15d-PGJ2 is a
known negative regulator of NF-κB activity [35,36], and this was con-
firmed by our data. NF-κB plays an important role in the regulation
of apoptosis by inhibiting or promoting apoptosis-regulating genes
[37]. Therefore, the proapoptotic effect of 15d-PGJ2 in B16 and
C26 cells might be due to the inhibition of NF-κB activity as demon-
strated in other cell types [38,39]. Of note, C26 cells were more sen-
sitive to the 15d-PGJ2 treatment than B16 cells as found repetitively in
the present study.
Several studies have found that 15d-PGJ2 loses its biologic activity
in vitro in the presence of serum [17,18], which was also confirmed
by us in this study. On the basis of the latter outcome, one may con-
clude that 15d-PGJ2 would become inactive in vivo because a large
amount of albumin is present in the circulation. However, our in vivo
data showed that treatment with 15d-PGJ2 substantially diminished
the growth of subcutaneous B16 tumors in mice. In addition, the
15d-PGJ2–treated tumors had higher damaged tumor tissue and dis-
rupted vasculature. In line with our data, 15d-PGJ2 has been shown
to cause apoptosis in endothelial cells [40], which might be the reason
for the disrupted vasculature in 15d-PGJ2–treated mice. Conversely,
no effect of 15d-PGJ2 in C26 tumors was seen, which is in contrast
to our in vitro studies. These data clearly indicate that 15d-PGJ2 re-
mained active after intravenous administration, but other factors gov-
ern the in vivo activity of 15d-PGJ2.
Inactivation of 15d-PGJ2 by serum proteins has been suggested as
an important factor [17]. Albumin has a free –SH group in cysteine 34
[41] that may produce a stable covalent bond with the electrophilic
cyclopentanone ring of 15d-PGJ2 [7]. However, our gel filtration chro-
matography data revealed that the binding of 15d-PGJ2 to albumin
(HSA or mouse albumin) was reversible. Also, the incomplete block-
ade of the 15d-PGJ2 effect by albumin in C26 cells in vitro (60% in-
hibition of the effect, see Figure 5D) at concentrations when nearly all
15d-PGJ2 was bound to albumin suggests reversibility of the binding in
C26 cells and may be due to the capacity of these cells to internalize the
complex (see Figure 5E). So, covalent binding and inactivation of 15d-
PGJ2 through binding to –SH groups of albumin are unlikely; more
likely, albumin serves as a reversible transport vehicle, transiently in-
activating 15d-PGJ2 and profoundly determining its body distribution.
Tumor vasculature is one of the most important factors regulating
the accumulation of macromolecules (>40 kDa) such as albumin in
tumors through a phenomenon referred to as enhanced permeability
and retention [42]. Infiltration of macromolecules is regulated by tu-
mor blood vessel density, blood vessel diameter and vascular perme-
ability. Our γ-camera imaging and anti-HSA immunostaining data
demonstrated that HSA distribution was much higher in B16 tumors
compared with C26 tumors, which was correlated with a larger blood
vessel lumen in B16 tumors than C26 tumors. Apparently, high
blood vessel density does not enhance HSA uptake in these tumors
because C26 tumors had significantly high blood vessel density but
low HSA uptake compared with B16 tumors. Our data suggest that
the antitumor effects of 15d-PGJ2 in B16 tumors are related to the high
HSA uptake in this tumor type, rather than to its sensitivity for 15d-
PGJ2. B16 tumors are more easily accessible for 15d-PGJ2–albumin
than C26 tumors. This might also be the reason that 15d-PGJ2 has
been found to display its therapeutic effects in many inflammatory
diseases such as cystitis, acute pancreatitis, ischemia-reperfusion in-
jury in gastric mucosa, brain, and kidneys [19,21–23,43,44] in animal
models as the albumin permeability is enhanced during inflammation
[45–48]. Because we showed that binding of 15d-PGJ2 to albumin is
reversible, 15d-PGJ2 can be released from the albumin–15d-PGJ2 com-
plex after permeabilization into the diseased organ or tumor.
Moreover, no fatalities and toxicity to liver and kidneys were
found after the multiple doses of 15d-PGJ2 in both tumor models,
which indicate that the applied doses were quite tolerable.
In conclusion, the present study shows that 15d-PGJ2 can be an
effective therapeutic agent for the treatment of cancer, but its effects
are dependent on the tumor permeability of albumin that is deter-
mined by the tumor vasculature. This will greatly determine the
rate of success of any study with 15d-PGJ2, and it should therefore
be taken into account before experimental or clinical studies with
15d-PGJ2 or similar compounds. In addition, this study suggests that
prevention of 15d-PGJ2 binding to albumin using drug delivery
strategies, such as incorporation into liposomes or conjugation to a
protein carrier, might provide a novel strategy to improve its in vivo
efficacy in tumors. 15d-PGJ2 is a lipophilic compound and therefore
can be incorporated into the lipid phase of liposomes. In addition,
15d-PGJ2 has a carboxylic group at the terminal that is not impor-
tant for its biologic activity but can be used for coupling to a protein
carrier, which may result in an improved efficacy in vivo.
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